Navigation Links
Nile Therapeutics, Inc. Adds to Executive Management Team
Date:9/21/2007

gement responsibilities at the James Black Foundation in London. Ms. Hodge received her Bachelor of Science degree in Biology with Honors in Pharmacology from the University of Edinburgh, UK.

"An effective management team is a great predictor of success. I am delighted to be working with such exceptionally talented people. Both Daron and Jenny have years of relevant cardiovascular therapy development experience. As a management team, we are focused on creating value through the development of our lead compound CD-NP for the treatment of heart failure and our pre-clinical, anti-atherothrombotic agent, 2NTX-99," said Peter Strumph, CEO of Nile Therapeutics.

About Nile Therapeutics.

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is developing innovative products for the treatment of cardiovascular disease. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel chimeric peptide in Phase I studies for the treatment of heart failure and 2NTX-99, a small molecule, pre-clinical, anti-atherothrombotic agent with nitric oxide (NO) donating properties.

CD-NP, a novel chimeric natriuretic peptide currently in Phase I clinical studies for the treatment of heart failure, is a selective NPRB agonist which, in vivo, has been shown to have potent renal enhancement and cardiac unloading properties but with minimal hypotensive effects compared with competitive products. CD-NP is a rationally-designed synthetic peptide designed to incorporate favorable properties of naturally occurring natriuretic peptides. Data from Nile's recently completed Phase Ia study in healthy volunteers confirmed several pre-clinical findings, including that CD-NP activated its target receptor in humans, preserved renal function and caused increases in natriuresis and diuresis at doses associated with a minimal effect on mean arterial pressure. Nile believes that CD-NP could provide a valuable new treatment option for heart fai
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Chemical-petroleum executive joins Virent Energy board
3. Visions: Matheys says CIO role is good training for executive suite
4. Biotech executive books a career flight thats closer to home
5. CEOs Gone Wild? Risks and rewards in the executive suite
6. Early-stage executives hear from investors
7. Pedlar the latest executive to leave Merge
8. Financial executives to launch Madison chapter
9. Former Thompson lawyer comments on Doyle stem cell executive order
10. Republican sees nothing wrong with Doyles use of executive order
11. Executives hear about promise, limits of RFID and nanotech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014 The ... today with $25,000 to fund a translational research ... in 2011, the gift was presented at the ... Annual Meeting in Colorado Springs, CO. ... in neurointerventional approaches to neurovascular conditions, SNIS formed ...
(Date:7/31/2014)... , July 31, 2014 Rogne Bioscience, ... Francisco Bay Area , has acquired a licence ... Oxford,s commercialisation company. The potent anti-inflammatory activity of the ... at the University of Oxford,s Sir William Dunn ... which has raised over $1.5 million in seed financing, ...
(Date:7/31/2014)... 31, 2014 North Shore Towers, a luxury ... with GI Energy, one of the nation’s leading combined heating ... upgrade of its 43-year-old CHP system. The original CHP system ... effort to extend the life of the plant, GI Energy ... electrical and heat recovery equipment, while maintaining continuous operation of ...
(Date:7/31/2014)... 31, 2014 Research and Markets ... Market 2014-2018" report to their offering. ... the study of the genetic material or genomes of ... basis for the discovery and development of diagnostic and ... health conditions. Genomics is supported by three major product ...
Breaking Biology Technology:SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 3Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 3North Shore Towers Partners with GI Energy to Install Turnkey Natural Gas-Fired Combined Heat and Power Plant 2Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina 2
... ... Just Test Instruments , ... (Vocus) April 25, 2010 -- Responding to the recent rash of reports of quality failures ... consultations on how to develop and maintain strict gage R&R for entire assembly and test ...
... PLANO, Texas , April 27 A non-profit organization is ... the full amount of its corporate donations.  "Unlike Coca-Cola, Pepsi refuses to ... Greg Quinlan , President of Parents and Friends of Ex-Gays & ... , "This ...
... April 27 Two months after launching a strategic review of ... has signed an agreement to sell United Media Licensing for $175 million ... , , ... the family of the late Charles Schulz , who created the beloved ...
Cached Biology Technology:InterTech Service to Counter Widely Reported Problems in Automotive, Medical Device and Other Industries Requiring Rigorous Quality Standards 2Pepsi Urged to Follow Example of Coca-Cola and Stop Hiding Corporate Donations 2Scripps Announces Sale of United Media's Licensing Business for $175 Million 2Scripps Announces Sale of United Media's Licensing Business for $175 Million 3
(Date:8/1/2014)... UC Davis Center for Neuroscience and Department of ... Engineering Faculty Fellowship from the U.S. Department of ... new work on learning and memory in Ranganath,s ... new project aims to connect neural oscillations, which ... cortex and hippocampus, brain regions that are known ...
(Date:8/1/2014)... Scientists examining a taxonomically confused group of marine ... science: the Australian humpback dolphin, Sousa sahulensis ... Clymene Enterprises. , The study describing the ... 17-year long systematic examination of all available historical ... dolphinsa widespread group of coastal cetaceans ranging from ...
(Date:8/1/2014)... research will provide enormous opportunities for both biological ... replicate any other cells in the body, offering ... spinal cords, treating kidney, liver and lung diseases ... profit is staggering. Prof. Jinhui Chen from Indiana ... research still faces myriad biological, ethical, legal, political, ...
Breaking Biology News(10 mins):Scientists name new species of cetacean: The Australian humpback dolphin 2Scientists name new species of cetacean: The Australian humpback dolphin 3
... 15, 2013 A team of investigators systematically analyzed the ... in a rigorous and controlled study of postmenopausal women. They ... symptoms reported by the participants. Their results are published in ... . The influence of low calcium and vitamin D ...
... more soft drinks per capita than people in any ... of all ages, including very young children. Although ... suicidal thoughts in adolescents, the relationship had not been ... for publication in The Journal of Pediatric s ...
... 15, 2013) Primary results from a new ... diabetes treated with the monoclonal antibody teplizumab (MacroGenics, ... of islet cell function, compared to controls. Further ... group that demonstrated especially robust responses ("responders"), suggesting ...
Cached Biology News:Calcium plus vitamin D supplementation does not reduce joint symptoms in postmenopausal women 2Soft drinks and behavioral problems in young children 2ITN type 1 diabetes study identifies subset of patients with strong response to therapy 2ITN type 1 diabetes study identifies subset of patients with strong response to therapy 3
For use with SSP products or any application requiring agarose gel separation • Multiple formats available to meet various throughput needs • Includes replacement parts for each un...
...
Request Info...
Human RUNX2/CBFA1 MAb (Clone 232902)...
Biology Products: